TITLE:
Bisphosphonate Treatment of Osteogenesis Imperfecta

CONDITION:
Osteogenesis Imperfecta

INTERVENTION:
Zoledronic Acid

SUMMARY:

      The primary purpose of this trial is to evaluate whether the investigational medication is
      safe, effective and has the ability to increase spine bone density in osteogenesis
      imperfecta (OI) patients.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 3 Months to 17 Years
Criteria:

        Inclusion

          -  Male or Female children between 3 months and 17 years old

          -  OI type I, III or IV

        Exclusion

          -  Deformity or abnormality which would prevent spine bone density from being done

          -  Any surgical bone-lengthening procedure

          -  Any kidney diseases or abnormalities

          -  Low calcium or vitamin D levels in the blood

        Other protocol-defined inclusion/exclusion criteria may apply.
      
